Sandoz has set out plans to launch in Brazil by the end of this year its Adalvo-partnered Owozy version of semaglutide, after local regulator Anvisa granted a marketing authorization.
Sandoz has set out plans to launch in Brazil by the end of this year its Adalvo-partnered Owozy version of semaglutide, after local regulator Anvisa granted a marketing authorization.